EPCAM and liver cancer: In this study, the levels of p-AKT, β-catenin, c-Myc, and EpCAM in hepatic cancer cells were decreased with the knockdown of SLC1A4, and the K63-dependent ubiquitin level of AKT protein was decreased with the knockdown of SLC1A4.